WCN26-3052 DEVELOPMENT OF NOVEL CELL THERAPIES USING FUNCTIONALLY ENHANCED HUMAN iPS CELL-DERIVED NEPHRON PROGENITOR CELLS FOR AKI AND CKD

Read full text Summarise with VIRAT
Authors: Toshikazu Araoka, Kosuke Toyohara, Takeya Otsuki, Maasa Matsuura, Kenji Osafune
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

With a 10–15% mortality rate and 20–30% of cases progressing to chronic kidney disease (CKD), acute kidney injury (AKI) affects an estimated 13.3 million people worldwide annually. In turn, CKD affects about 850 million people and is expected to become the fifth leading cause of death globally by 2030. With kidney transplantation as the only curative therapy, a growing dependency on dialysis has arisen due to donor shortages and limited treatments for AKI and CKD, which also raise the risk of cardiovascular and cerebrovascular diseases.

Fields of Study & Subjects

Acute Kidney Injury Research Renal and related cancers Pluripotent Stem Cells Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105805–105805
Publication date
25 March 2026
Language
EN